EQUILLIUM, INC. Research and Development Expense
EQUILLIUM, INC. (EQ) reported Research and Development Expense of $37.04 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-03-25
- EQUILLIUM, INC. research and development expense for the quarter ending 2021-12-31 was $7.55M, a 14.95% increase year-over-year.
- EQUILLIUM, INC. research and development expense for the quarter ending 2021-09-30 was $6.96M, a 65.13% increase year-over-year.
- EQUILLIUM, INC. research and development expense for the quarter ending 2021-06-30 was $5.99M, a 53.74% increase year-over-year.
- EQUILLIUM, INC. research and development expense for the quarter ending 2021-03-31 was $5.88M, a 24.95% increase year-over-year.
- EQUILLIUM, INC. research and development expense for fiscal 2023 was $37.04M, a 1.35% decline from fiscal 2022.
- EQUILLIUM, INC. research and development expense for fiscal 2022 was $37.55M, a 42.34% increase from fiscal 2021.
- EQUILLIUM, INC. research and development expense for fiscal 2021 was $26.38M, a 36.09% increase from fiscal 2020.
- EQUILLIUM, INC. research and development expense for fiscal 2020 was $19.38M, a 9.89% increase from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 7 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 10 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $37.04M 10-K · filed 2024-03-25 | ||||||||
| 2022-12-31 | $37.55M 10-K · filed 2024-03-25 | ||||||||
| 2021-12-31 | $7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $14.51M derived: sum of 2 quarters · filed 2023-03-23 | $20.50M derived: sum of 3 quarters · filed 2023-03-23 | $26.38M 10-K · filed 2023-03-23 | |||||
| 2021-09-30 | $6.96M 10-Q · filed 2021-11-10 | $12.95M derived: sum of 2 quarters · filed 2021-11-10 | $18.83M 10-Q · filed 2021-11-10 | $25.40M derived: sum of 4 quarters · filed 2022-03-23 | |||||
| 2021-06-30 | $5.99M 10-Q · filed 2021-08-10 | $11.87M 10-Q · filed 2021-08-10 | $18.43M derived: sum of 3 quarters · filed 2022-03-23 | $22.65M derived: sum of 4 quarters · filed 2022-03-23 | |||||
| 2021-03-31 | $5.88M 10-Q · filed 2021-05-13 | $12.45M derived: sum of 2 quarters · filed 2022-03-23 | $16.66M derived: sum of 3 quarters · filed 2022-03-23 | $20.56M derived: sum of 4 quarters · filed 2022-03-23 | |||||
| 2020-12-31 | $6.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $10.79M derived: sum of 2 quarters · filed 2022-03-23 | $14.68M derived: sum of 3 quarters · filed 2022-03-23 | $19.38M 10-K · filed 2022-03-23 | |||||
| 2020-09-30 | $4.22M 10-Q · filed 2021-11-10 | $8.11M derived: sum of 2 quarters · filed 2021-11-10 | $12.82M 10-Q · filed 2021-11-10 | $18.27M derived: sum of 4 quarters · filed 2021-11-10 | |||||
| 2020-06-30 | $3.89M 10-Q · filed 2021-08-10 | $8.60M 10-Q · filed 2021-08-10 | $14.05M derived: sum of 3 quarters · filed 2021-08-10 | $18.23M derived: sum of 4 quarters · filed 2021-08-10 | |||||
| 2020-03-31 | $4.71M 10-Q · filed 2021-05-13 | $10.15M derived: sum of 2 quarters · filed 2021-05-13 | $14.34M derived: sum of 3 quarters · filed 2021-05-13 | $18.59M derived: sum of 4 quarters · filed 2021-05-13 | |||||
| 2019-12-31 | $5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $9.63M derived: sum of 2 quarters · filed 2021-03-24 | $13.88M derived: sum of 3 quarters · filed 2021-03-24 | $17.64M 10-K · filed 2021-03-24 | |||||
| 2019-09-30 | $4.18M 10-Q · filed 2020-11-10 | $8.43M derived: sum of 2 quarters · filed 2020-11-10 | $12.19M 10-Q · filed 2020-11-10 | $14.71M derived: sum of 4 quarters · filed 2020-11-10 | |||||
| 2019-06-30 | $4.25M 10-Q · filed 2020-08-12 | $8.01M 10-Q · filed 2020-08-12 | $10.53M derived: sum of 3 quarters · filed 2020-08-12 | $11.75M derived: sum of 4 quarters · filed 2020-08-12 | |||||
| 2019-03-31 | $3.76M 10-Q · filed 2020-05-13 | $6.28M derived: sum of 2 quarters · filed 2020-05-13 | $7.50M derived: sum of 3 quarters · filed 2020-05-13 | $8.04M derived: sum of 4 quarters · filed 2020-05-13 | |||||
| 2018-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $3.74M derived: sum of 2 quarters · filed 2020-03-26 | $4.28M derived: sum of 3 quarters · filed 2020-03-26 | $4.94M 10-K · filed 2020-03-26 | $4.94M 10-K · filed 2019-03-27 | ||||
| 2018-09-30 | $1.22M 10-Q · filed 2019-11-12 | $1.22M 10-Q · filed 2018-11-15 | $1.76M derived: sum of 2 quarters · filed 2019-11-12 | $2.42M 10-Q · filed 2019-11-12 | $2.43M 10-Q · filed 2018-11-15 | ||||
| 2018-06-30 | $540.00K 10-Q · filed 2019-08-12 | $1.20M 10-Q · filed 2019-08-12 | |||||||
| 2018-03-31 | $663.00K 10-Q · filed 2019-05-13 | ||||||||
| 2017-12-31 | $1.33M 10-K · filed 2019-03-27 | ||||||||
| 2017-09-30 | $49.95K 10-Q · filed 2018-11-15 | $851.31K 10-Q · filed 2018-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |